Composition for preventing or treating lung disease comprising CD47-overexpressing mesenchymal stem cells

CD47-overexpressing mesenchymal stem cells provide a therapeutic solution for lung diseases by reducing inflammation and fibrosis, effectively treating conditions like asthma and pulmonary fibrosis.

JP2024543218APending Publication Date: 2024-11-19MEDIPOST
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024532901
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-01
Filing Date
2022-09-21
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Current therapeutic agents are ineffective in simultaneously addressing inflammation and fibrosis in lung diseases such as asthma, COPD, and pulmonary fibrosis, which can lead to irreversible lung damage and complications.

Method used

A pharmaceutical composition containing mesenchymal stem cells that overexpress CD47, engineered to enhance their anti-inflammatory and anti-fibrotic effects, is administered to treat lung diseases.

Benefits of technology

The CD47-overexpressing mesenchymal stem cells reduce inflammation and fibrosis in lung tissue, improving lung function and reducing the progression of diseases like asthma and pulmonary fibrosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543218000001_ABST
    Figure 2024543218000001_ABST
Patent Text Reader

Abstract

This relates to a composition for preventing or treating pulmonary diseases, which contains mesenchymal stem cells that overexpress CD47 as an active ingredient. Mesenchymal stem cells that overexpress CD47 exhibit high survival rates in the body and the ability to migrate to lung tissue, even when not derived from the body itself, and have the effect of reducing inflammatory responses in lung tissue and suppressing fibrosis. Therefore, they can be widely used in the prevention or treatment of various pulmonary diseases associated with pulmonary inflammation or fibrosis.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a pharmaceutical composition for preventing or treating lung diseases, which comprises mesenchymal stem cells that overexpress CD47 as an active ingredient. [Background technology]

[0002] The lung is an essential organ in the human body that is responsible for breathing, obtaining oxygen and expelling carbon dioxide by inhaling and exhaling air. The lung functions to maintain vital phenomena, and bodily fluid components are actively absorbed or expelled through epithelial cells in the lung, and in some cases, it also serves as a pathway for the delivery of inhaled drugs.

[0003] Asthma, a representative disease among such lung diseases, has doubled in incidence over the past 20 years, and today, 8-10% of the world's population suffers from it. It is mainly caused by chronic inflammation of the airways. Asthma is characterized by airway hyperresponsiveness (AHR) to nonspecific stimuli and airway remodeling, the latter of which involves a dynamic process that causes cellular changes in fibroblasts and myofibroblasts and structural changes in the airways. There are two types of asthma: bronchial asthma and cardiac asthma, but simply asthma usually means bronchial asthma. Repeated asthma attacks can cause fibrosis and airway remodeling, which can lead to a permanent decline in lung function.

[0004] Chronic obstructive pulmonary disease (COPD), which is one of the most common lung diseases along with asthma, differs from asthma in that it causes irreversible airway obstruction. It is a disease caused by pathological changes in the bronchioles and lung parenchyma of the lungs due to inflammation of the airways and lung parenchyma, and is characterized by obstructive bronchiolitis and emphysema. Types of chronic obstructive pulmonary disease include chronic obstructive bronchitis, chronic bronchiolitis, and emphysema, and are known to cause symptoms such as dyspnea, cough, and sputum, and to appear in the majority of chronic bronchitis patients.

[0005] Pulmonary fibrosis is a type of chronic interstitial lung disease that causes severe respiratory disorders due to the infiltration of inflammatory cells such as lymphocytes and macrophages into the pulmonary interstitium, proliferation of fibroblasts, and deposition of fibrous connective tissue in the pulmonary interstitium. As pulmonary fibrosis progresses, various complications appear, including systemic hypoxia caused by reduced lung capacity and impaired oxygen diffusion, pulmonary hypertension caused by compression of the pulmonary arteries and capillaries due to contraction of fibrous tissue, heart failure caused by blood pooling in the right ventricle due to impaired pulmonary circulation, thrombosis, pneumonia, etc. In addition, inflammation and fibrosis can increase the incidence of lung cancer.

[0006] As described above, most of the various lung diseases are associated with inflammation or fibrosis, and no therapeutic drug for lung diseases that can simultaneously improve these conditions has been known until now.

[0007] Therefore, the inventors made extensive efforts to effectively treat various lung diseases associated with inflammation or fibrosis without side effects, and discovered that mesenchymal stem cells derived from umbilical cord blood that overexpress CD47 have anti-inflammatory and anti-fibrotic effects, leading to the completion of the present invention. Summary of the Invention [Problem to be solved by the invention]

[0008] An object of the present invention is to provide a medical composition for preventing or treating lung diseases, which has anti-inflammatory and anti-fibrotic effects.

[0009] Another object of the present invention is to provide a method for treating a lung disease, comprising the step of administering to a subject a composition containing, as an active ingredient, mesenchymal stem cells expressing CD47.

[0010] It is still another object of the present invention to provide a use of mesenchymal stem cells expressing CD47 for the manufacture of a therapeutic agent for the treatment of lung diseases. [Means for solving the problem]

[0011] To achieve the above object, one aspect provides a medical composition for preventing or treating lung diseases, comprising mesenchymal stem cells expressing CD47 as an active ingredient.

[0012] The term "CD47 (Cluster of Differentiation 47)", also known as integrin associated protein (IAP), refers to a cell surface glycoprotein expressed on human cells that binds to the ligands thrombospondin-1 (TSP-1) and signal-regulatory protein alpha (SIRPα). It is known that suppressing CD47 expression in tumor tissues has therapeutic effects on several cancers by triggering phagocytosis of T cell-mediated adaptive immunity targeting CTLA and PD-1. Activation of CD47 has been shown to correlate with enhanced cancer cell proliferation via the P13K / Akt pathway. In addition to immune responses, CD47 is involved in various cellular processes including apoptosis, proliferation, adhesion and migration.

[0013] The term "mesenchymal stem cells (MSCs)" refers to stem cells differentiated from mesoderm resulting from the division of a fertilized egg and present in cartilage, bone tissue, adipose tissue, bone marrow stroma, etc., and can include mesenchymal stem cells of animals including mammals, such as humans. Mesenchymal stem cells maintain stemness and self-renewal, and have the ability to differentiate into various cells including chondrocytes, osteoblasts, muscle cells, and adipocytes, and can be extracted from bone marrow, adipose tissue, umbilical cord blood, synovial membrane, trabecular bone, muscle, infrapatellar fat pad, etc. Mesenchymal stem cells have the immunoregulatory ability to inhibit the activation and proliferation of T and B lymphocytes, suppress the activity of natural killer cells (NK cells), and regulate the functions of dendritic cells and macrophages, making them suitable for allotransplantation and xenotransplantation.

[0014] The mesenchymal stem cells may be genetically engineered to increase expression of CD47.

[0015] The terms "genetic engineering" or "genetically engineered" can refer to the act of introducing at least one genetic modification into a cell.

[0016] The increased expression or overexpression can refer to a higher level of expression of a protein of the same type as compared to the endogenous expression of the same protein in a given genetically unengineered blast cell (e.g., wild type).

[0017] The genetically engineered mesenchymal stem cells may comprise a recombinant vector into which an exogenous gene encoding CD47 has been introduced.

[0018] In one embodiment, mesenchymal stem cells that overexpress CD47 can be produced using a viral vector into which an exogenous gene encoding CD47 has been introduced.

[0019] The exogenous gene may be expressed in an amount sufficient to increase the activity of CD47 in the mesenchymal stem cell or the host cell compared to the parent cell. The exogenous gene may be introduced into the cell via an expression vector. The exogenous gene may be introduced into the cell in the form of a linear polynucleotide. The exogenous gene may be expressed in the cell from an expression vector (e.g., a plasmid). The exogenous gene may be inserted into genetic material (e.g., a chromosome) in the cell for stable expression and expressed. The exogenous gene may be appropriately regulated by an exogenous promoter operably linked to the gene. The expression level of the polynucleotide may be enhanced by modification such as substitution or mutation of an expression control sequence, introduction of a mutation in the polynucleotide sequence itself, mutation of the start codon, insertion into a chromosome, or increase in copy number by introduction by a vector, or a combination thereof.

[0020] The term "operably linked" refers to a functional bond between a control sequence (e.g., a promoter) and the polynucleotide sequence, such that the control sequence regulates the transcription and / or translation of the polynucleotide sequence. The control sequence may be a strong promoter capable of increasing the expression level of the polynucleotide. The control sequence may be a promoter derived from the genus Corynebacterium or other microorganisms. The promoter may be, for example, a trc promoter, a gap promoter, a tac promoter, a T7 promoter, a lac promoter, a trp promoter, an araBAD promoter, or a cj1-7 promoter. The control sequence may be, for example, a promoter sequence of a major gene in the lysine biosynthetic pathway in a microorganism of the genus Corynebacterium modified to have a higher promoter activity.

[0021] The term "vector" may refer to a polynucleotide product containing a gene regulatory sequence and a base sequence so that a target gene can be expressed in a suitable host cell. Alternatively, it may refer to a polynucleotide product containing a base sequence capable of homologous recombination so that a regulatory sequence of an endogenous gene on the genome of the host can be changed or an expressible target gene can be inserted at a specific site on the genome when it is introduced into the host cell. Thus, the vector may further include a selection marker for confirming whether it has been introduced into the host or inserted into a chromosome, and the selection marker may be a marker that confers a selectable phenotype such as drug resistance, auxotrophy, resistance to cytotoxicity, or expression of a surface protein. In an environment treated with a selection agent, only cells expressing the selection marker survive or show other phenotypes, so that transformed cells can be selected. The vector may be a plasmid vector, a lentivirus vector, a cosmid vector, a bacteriophage vector, an adenovirus vector, a retrovirus vector, or a combination thereof. and viral vectors such as adeno-associated virus vectors. Vectors that can be used as the recombinant vectors can be prepared by manipulating plasmids (e.g., pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8 / 9, pUC6, pBD9, pHC79, pIJ61, pLAFR1, pHV14, pGEX series, pET series, pUC19, etc.), phages (e.g., λgt4λB, λ-Charon, λΔz1, and M13, etc.) or viruses (e.g., SV40, etc.) that are frequently used in the art.

[0022] The recombinant vector can typically be constructed as a vector for cloning or a vector for expression. The expression vector can be a vector commonly used in the art for expressing foreign proteins in plants, animals, or microorganisms. The recombinant vector can be constructed by various methods known in the art.

[0023] The recombinant vector can be constructed using prokaryotic or eukaryotic cells as hosts. For example, when the vector used is an expression vector and a prokaryotic cell is used as a host, it usually contains a strong promoter (e.g., pLλ promoter, CMV promoter, trp promoter, lac promoter, tac promoter, T7 promoter, etc.) that can drive transcription, a ribosome binding site for translation initiation, and a transcription / translation termination sequence. When a eukaryotic cell is used as a host, the replication origin contained in the vector that functions in a eukaryotic cell includes, but is not limited to, the f1 replication origin, SV40 replication origin, pMB1 replication origin, adeno replication origin, AAV replication origin, and BBV replication origin. In addition, a promoter derived from the genome of a mammalian cell (e.g., metallothionine promoter) or a promoter derived from a mammalian virus (e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus promoter, and HSV tk promoter) can be used, and generally has a polyadenylation sequence as a transcription termination sequence.

[0024] The recombinant cell may be obtained by introducing the recombinant vector into a suitable host cell. The host cell is a cell capable of stably and continuously cloning or expressing the recombinant vector, and may be any host cell known in the art. Examples of prokaryotic cells include strains of the genus Bacillus, such as E. coli JM109, E. coli BL21, E. coli RR1, E. coli LE392, E. coli B, E. coli X1776, E. coli W3110, Bacillus subtilis, Bacillus thuringiensis, and Enterobacteriaceae, such as Salmonella typhimurium, Serratia marcescens, and various Pseudomonas species. In the case of transformation into eukaryotic cells, host cells include yeast (Saccharomyce cerevisiae), insect cells, plant cells, and animal cells, such as Sp2 / 0, CHO (Chinese hamster ovary) K1, CHO DG44, PER.C6, W138, BHK, COS-7, 293, HepG2, Huh7, 3T3, RIN, MDCK cell lines, etc. can be used.

[0025] The mesenchymal stem cells may be derived from any one selected from the group consisting of umbilical cord, umbilical cord blood, placenta, bone marrow, adipose tissue, muscle, amniotic fluid, amniotic membrane, and dental pulp.

[0026] The terms "isolated cells", e.g., "isolated mesenchymal stem cells" or "cells derived from", e.g., "derived mesenchymal stem cells", etc., refer to cells that have been substantially isolated from the tissue from which they are derived, e.g., umbilical cord blood.

[0027] The umbilical cord is the organ that allows a mammalian fetus to grow within the placenta. It can refer to the cord that connects the mother to the navel so that the baby can be delivered to the womb, or it can refer to the tissue that generally consists of three blood vessels, two umbilical arteries and one umbilical vein, surrounded by Wharton's jelly; it is also called the umbilical cord.

[0028] The umbilical cord blood may refer to blood collected from the umbilical vein that connects the placenta and fetus of a mammal. The umbilical cord blood may be easily collected from the umbilical vein of a donor at the time of birth. Specifically, in the case of normal vaginal delivery, the blood may be collected from the umbilical vein delivered to the outside of the uterus after birth while the placenta is still in the uterus, and in the case of Caesarean section, the blood may be collected from the umbilical vein after birth while the placenta is also delivered to the outside of the uterus.

[0029] In one embodiment, the mesenchymal stem cells may be derived from umbilical cord blood.

[0030] The mesenchymal stem cells may be such that 20% to 99% of a cell population expresses CD47.

[0031] The mesenchymal stem cells may be such that at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or about 99%, or 30% to 100%, 30% to 99%, 30% to 98%, 30% to 97%, 40% to 99%, 50% to 99%, 60% to 99%, 70% to 99%, 80% to 99%, or 90% to 99% of the cell population expresses CD47.

[0032] In one embodiment, it can be confirmed that approximately 29% of a control mesenchymal stem cell population expresses CD47, and approximately 96% of a mesenchymal stem cell population containing a recombinant vector into which an exogenous gene encoding CD47 has been introduced expresses CD47.

[0033] Specifically, 20%-85%, 20%-70%, 20%-60%, 25%-50% of the non-genetically engineered mesenchymal stem cell population can express CD47, and 80%-100%, 85%-99%, 90%-99% of the genetically engineered mesenchymal stem cell population can express CD47.

[0034] The mesenchymal stem cells may i) be positive for at least one marker selected from the group consisting of CD90, CD105, CD73 and CD166, and ii) be negative for CD14 or HLA-DR markers.

[0035] The term "positive or (+)" can mean, with respect to a mesenchymal stem cell specific marker, that the marker is present in a greater amount or at a higher concentration compared to other reference cells. That is, a cell is positive for a marker if the marker is present inside or on the cell and can be used to distinguish the cell from at least one other cell type. It can also mean that the cell expresses the marker in an amount sufficient to produce a signal, e.g., a signal from a cell measuring device, above background. For example, a cell can be detectably labeled with a CD90-specific antibody, and if the signal from the antibody is detectable above a control (e.g., background), the cell is "CD90+".

[0036] The term "negative or (-)" can mean that the labeling cannot be detected using an antibody specific for a particular cell marker compared to background values. For example, if a cell cannot be detectably labeled with an antibody specific for CD14, then the cell is "CD14-".

[0037] In one embodiment, it can be confirmed that the genetically engineered CD47-overexpressing mesenchymal stem cell population and the non-genetically engineered mesenchymal stem cell population similarly express 98% or more of the CD90, CD105, CD73 and CD166 markers, and 1% or less of the CD14 and HLA-DR markers. Therefore, it can be confirmed that the genetically engineered CD47-overexpressing mesenchymal stem cells also maintain the specific properties of mesenchymal stem cells.

[0038] The mesenchymal stem cells may be positive for at least one marker selected from the group consisting of CD9, CD13, CD29, CD44, CD73, CD90, CD105, CD166, and HLA-abc.

[0039] The mesenchymal stem cells may be negative for at least one marker selected from the group consisting of CD2, CD3, CD4, CD5, CD7, CD8, CD14, CD15, CD16, CD19, CD20, CD22, CD33, CD36, CD38, CD61, CD62E, CD133 and HLA-DR.

[0040] The mesenchymal stem cells may exhibit reduced immunogenicity.

[0041] In one embodiment, it can be confirmed that the apoptotic effect caused by activated PBMCs and NK cells is reduced when CD47-overexpressing mesenchymal stem cells are co-cultured with PBMCs or NK cells. Therefore, when CD47-overexpressing mesenchymal stem cells are administered, even if they are not autologous, they can avoid immune reactions caused by activated PBMCs or NK cells, thereby increasing the in vivo survival rate of the administered cells.

[0042] The pulmonary disorder may be, but is not limited to, asthma, pneumonia, chronic obstructive pulmonary disease, bronchitis, emphysema, pulmonary hypertension or pulmonary fibrosis.

[0043] The mesenchymal stem cells are capable of reducing inflammatory responses in lung tissue.

[0044] The mesenchymal stem cells can decrease M1 macrophages and increase M2 macrophages.

[0045] M1 macrophages induce inflammatory responses, whereas M2 macrophages play a role in reducing inflammatory responses and repairing damaged tissues.

[0046] In one embodiment, CD47-overexpressing mesenchymal stem cells were intravenously administered to a mouse model of asthma, and it was confirmed that the CD47-overexpressing mesenchymal stem cells migrated to lung tissue, reduced the expression of M1 macrophage-specific markers that induce inflammatory responses in lung tissue, and increased the expression of M2 macrophage-specific markers that repair damaged tissue. It was also confirmed that the expression of inflammatory cytokines and the number of neutrophil cells in bronchoalveolar lavage fluid (BALF) of the mouse model of asthma were reduced.

[0047] Therefore, CD47-overexpressing mesenchymal stem cells can be used to prevent or treat diseases associated with inflammatory responses in lung tissue, including asthma.

[0048] Mesenchymal stem cells that overexpress the CD47 can reduce the expression of α-SMA (α-smooth muscle actin) and MMP-13 (matrix metalloproteinase-13).

[0049] In one embodiment, it can be confirmed that the expression of fibrosis-specific markers is reduced as a result of co-culturing CD47-overexpressing mesenchymal stem cells with human pulmonary fibroblasts (HPF).

[0050] Therefore, CD47-overexpressing mesenchymal stem cells can be used to prevent or treat diseases associated with fibrosis of lung tissue, including fibrosis.

[0051] Another aspect provides a medical composition for preventing or treating a lung disease, comprising a CD47-overexpressing mesenchymal stem cell culture as an active ingredient.

[0052] The CD47-overexpressing mesenchymal stem cell culture is obtained by subculturing CD47-overexpressing mesenchymal stem cells in an appropriate medium to obtain a culture solution, and then filtering the culture solution.

[0053] Another embodiment provides a cellular therapeutic agent or pharmaceutical composition comprising, as an active ingredient, a CD47-overexpressing mesenchymal stem cell or a cell population thereof.

[0054] The cell therapy drug or pharmaceutical composition may be for the prevention or treatment of a lung disease.

[0055] Yet another embodiment provides a use of CD47-overexpressing mesenchymal stem cells or a population of such cells for the manufacture of a medicament.

[0056] According to one embodiment, the use may be for the manufacture of a therapeutic agent for using mesenchymal stem cells expressing CD47 in the treatment of lung disease.

[0057] Yet another embodiment provides a method for treating a pulmonary disease comprising administering to a subject a therapeutically or pharmacologically effective amount of CD47-overexpressing mesenchymal stem cells or a population of cells thereof.

[0058] The cellular therapy or pharmaceutical composition can be administered to a patient in a therapeutically effective amount or a pharmacologically effective amount.

[0059] The term "treatment" means or includes the alleviation, inhibition of progression, or prevention of a disease, disorder, or condition, or one or more symptoms thereof, and "active ingredient" can mean a cell population or composition effective in alleviating, inhibiting progression, or preventing a disease, disorder, or condition, or one or more symptoms thereof.

[0060] The terms "administer", "introduce" and "implant" are used interchangeably and may refer to placing a composition according to an embodiment of the present invention at a desired site by a method or route that results in at least partial localization in a subject. Administration may be by any suitable route that delivers at least a portion of the cells or cellular components of a composition according to an embodiment to a desired location in a living subject. The survival period of the cells after administration to a subject may be as short as a few hours, e.g., 24 hours to several days, or as long as several years. The medical composition may be administered to a patient in a therapeutically effective amount or a pharmacologically effective amount.

[0061] The term "therapeutically effective amount" or "pharmacologically effective amount" refers to an amount of a cell population or composition effective in preventing or treating a pulmonary disease, sufficient to treat the disease at a reasonable benefit / risk ratio applicable to any medical treatment, and not causing side effects. The level of the effective amount will vary depending on factors including the patient's health condition, the type and severity of the disease, the activity of the drug, sensitivity to the drug, the method, time, route and excretion rate of administration, duration of treatment, co-administered or concomitant drugs, and other factors well known in the medical arts. is determined.

[0062] The pharmaceutical compositions can be administered as individual therapeutic agents or in combination with other therapeutic agents, can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered in single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that provides maximum efficacy with minimal side effects, and this can be easily determined by one of ordinary skill in the art.

[0063] Specifically, in the medical composition, the effective amount of the CD47-overexpressing mesenchymal stem cells varies depending on the age, sex, and weight of the patient, and is generally about 1×10 6 ~1×10 7 The cells can be administered once or repeatedly. The range is not limited thereto, as it may increase or decrease depending on the route of administration, severity of the disease, sex, weight, age, etc.

[0064] In consideration of the complexity of this specification, duplicate content will be omitted, and terms not otherwise defined in this specification have the meanings commonly used in the technical field to which the present invention pertains. Effect of the Invention

[0065] In one embodiment, mesenchymal stem cells overexpressing CD47 exhibit high survival rates and migration capabilities to lung tissue in the body even when not derived from the body itself, and have the effect of reducing inflammatory responses in lung tissue and inhibiting fibrosis, and therefore can be widely used for the prevention or treatment of various lung diseases associated with pulmonary inflammation or fibrosis. [Brief description of the drawings]

[0066] [Figure 1] FIG. 1 is a diagram (photograph substituting a drawing) showing the results of confirming the CD47 expression rate of CD47-overexpressing mesenchymal stem cells (MSC OE) according to one embodiment and control mesenchymal stem cells (MSC VC). [Diagram 2] FIG. 2 is a diagram showing the results of comparing the expression levels of mesenchymal stem cell-specific markers between CD47-overexpressing mesenchymal stem cells (MSC OE) according to one embodiment and control mesenchymal stem cells (MSC VC). [Diagram 3] FIG. 3 is a diagram (photograph in lieu of drawing) showing the results of comparing the effects of administering CD47-overexpressing mesenchymal stem cells (MSC OE) according to one embodiment and control mesenchymal stem cells (MSC V.) to a mouse model of asthma, and comparing their effects on improving inflammation in lung tissue. [Figure 4] FIG. 4 is a photograph (drawing substitute) showing the results of immunocytochemical staining of changes in expression of CD11b, an M1 macrophage-specific marker, in lung tissue after administration of CD47-overexpressing mesenchymal stem cells (MSC OE) according to one embodiment and control mesenchymal stem cells (MSC V.) to a mouse model of asthma. [Diagram 5]FIG. 5 shows the results of measuring the number of cells expressing CD11b, an M1 macrophage-specific marker, in lung tissue after administration of CD47-overexpressing mesenchymal stem cells according to one embodiment (MSC OE) and control mesenchymal stem cells (MSC V.) to a mouse model of asthma. [Figure 6] FIG. 6 is a diagram (photograph in lieu of drawing) showing the results of immunocytochemical staining to confirm the change in expression of CD163, an M2 macrophage-specific marker, in lung tissue after administration of CD47-overexpressing mesenchymal stem cells (MSC OE) according to one embodiment and control mesenchymal stem cells (MSC V.) to a mouse model of asthma. [Figure 7] FIG. 7 shows the results of measuring the number of cells expressing CD163, an M2 macrophage cell-specific marker, in lung tissue after administering CD47-overexpressing mesenchymal stem cells (MSC OE) according to one embodiment and control mesenchymal stem cells (MSC V.) to a mouse model of asthma. [Figure 8] FIG. 8 is a diagram (photograph in lieu of drawing) showing the results of immunocytochemical staining to confirm whether or not CD47-overexpressing mesenchymal stem cells (MSC OE) according to one embodiment and control mesenchymal stem cells (MSC V.) migrate to lung tissue after intravenous administration to a mouse model of asthma. [Figure 9] FIG. 9 shows the results of measuring the number of CD47-overexpressing mesenchymal stem cells that migrated into lung tissue after intravenous administration of CD47-overexpressing mesenchymal stem cells according to one embodiment (MSC OE) and control mesenchymal stem cells (MSC V.) to a mouse model of asthma. [Figure 10] FIG. 10 shows the results of confirming changes in expression of inflammatory cytokines in bronchoalveolar lavage fluid (BALF) after administering CD47-overexpressing mesenchymal stem cells (MSC OE) according to one embodiment and control mesenchymal stem cells (MSC V.) to an asthma model. [Figure 11]FIG. 11 shows the results of confirming the change in neutrophil cell count in BALF after administration of CD47-overexpressing mesenchymal stem cells according to one embodiment (MSC OE) and control mesenchymal stem cells (MSC V.) to an asthma model. [Figure 12] FIG. 12 is a diagram (photograph in lieu of drawing) showing the results of confirming the change in survival of mesenchymal stem cells by immunocytochemical staining after co-culturing CD47-overexpressing mesenchymal stem cells (MSC OE) according to one embodiment and control mesenchymal stem cells (MSC V.) with activated peripheral blood mononuclear cells (PBMC). [Figure 13] FIG. 13 shows the results of measuring the viability of mesenchymal stem cells after co-culturing CD47-overexpressing mesenchymal stem cells (MSC OE) according to one embodiment and control mesenchymal stem cells (MSC V.) with PBMCs. [Figure 14] FIG. 14 is a diagram (photograph substituting a drawing) showing the results of confirming the change in survival of mesenchymal stem cells by immunocytochemical staining after co-culturing CD47-overexpressing mesenchymal stem cells (MSC OE) according to one embodiment and control mesenchymal stem cells (MSC V.) with activated natural killer cells (NK cells). [Figure 15] FIG. 15 shows the results of measuring the viability of mesenchymal stem cells after co-culturing CD47-overexpressing mesenchymal stem cells (MSC OE) according to one embodiment and control mesenchymal stem cells (MSC V.) with activated NK cells. [Figure 16] FIG. 16 shows the results of confirming changes in the expression levels of fibrosis-specific markers after co-culturing CD47-overexpressing mesenchymal stem cells (MSC OE) according to one embodiment and control mesenchymal stem cells (MSC V.) with human pulmonary fibroblasts (HPF). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0067] The present invention will be described in more detail below with reference to examples. However, these examples are merely for illustrative purposes and are not intended to limit the scope of the present invention.

[0068] <Production Example 1. Isolation of mesenchymal stem cells from umbilical cord blood>

[0069] Donor umbilical cord blood obtained from the umbilical vein of healthy women donated during childbirth with their consent was centrifuged using a Ficoll-Hypaque gradient to obtain mononuclear cells, which were then cultured in mesenchymal stem cell culture medium to obtain mesenchymal stem cells derived from umbilical cord blood.

[0070] <Production Example 2. Production of CD47-overexpressing mesenchymal stem cells>

[0071] To generate lentivirus expressing CD47, the CD47 ORF (open reading frame) sequence was inserted into the plenti-suCMV-RSV-GFP vector using the EZ-Fusion HT Cloning Kit (#EZ015) (Enzynom The vectors were cloned using a vector cloner (InvivoGen, Inc.). The plenti-suCMV-RSV-GFP-CD47, pMD2.G and psPAX2 vectors were transfected into 293T cells to package the lentivirus. The medium containing the viral particles was collected and treated with mesenchymal stem cells to transduce them. CD47-overexpressing mesenchymal stem cells (Overexpression, OE) were produced by treating the cells with the antibiotic puromycin (#ant-pr-1) (InvivoGen, Inc.) for 2 days to select and culture only the transduced stem cells. The control mesenchymal stem cells (Vector control; VC) for CD47 expression and function analysis were produced by lentivirus packaging, transduction and antibiotic selection in the same manner as the production of the CD47-overexpressing mesenchymal stem cells, using the backbone vector plenti-suCMV-RSV-GFP. EXAMPLES

[0072] Example 1. Characterization of CD47-overexpressing mesenchymal stem cells

[0073] To analyze the characteristics of the CD47-overexpressing mesenchymal stem cells prepared in Preparation Example 2, Western blot and flow cytometry were performed as follows. Cytometry was performed.

[0074] More specifically, the Western blotting method was described. Control mesenchymal stem cells and CD47-overexpressing mesenchymal stem cells were treated with RIPA Lysis buffer (#78440) (Thermo Scientific) and incubated on ice for 30 minutes to disrupt the cells. The cell lysate was centrifuged, and only the supernatant was collected and quantified using a BCA protein quantification kit (#23225) (Thermo Scientific). 10 μg of protein extract was separated using 10% SDS-PAGE and then transferred to a membrane. After incubation with blocking buffer (0.1% Tween 20, 5% BSA-containing Tris-buffered saline) for 1 hour at room temperature, the cells were treated with a primary antibody and incubated overnight at 4°C. Primary antibodies used included CD47 (#MA5-11895) (Thermo Scientific) and b-actin (#A5441) (Sigma). After washing three times with TBST, the secondary antibody was reacted at room temperature for 1 hour, and after washing, the protein bands were analyzed using a ChemiDoc MP System (Bio-Rad).

[0075] To confirm the overexpression of CD47 on the cell surface, flow cytometry was performed. More specifically, cells were stained with PE mouse anti-human CD47 (#556046) (BD Biosciences) for 15 min at room temperature for flow cytometry of CD47 protein expression. The corresponding PE mouse IgG1, k isotype (#555749) (BD Biosciences) was used as a control. After washing once with PBS, cells were fixed with 1% PFA and protein expression was analyzed using a MACSQuant instrument (MACS Quantify), and the results are shown in Figure 1.

[0076] As shown in Figure 1, we confirmed that the CD47 protein expression level was significantly increased in the CD47-overexpressing stem cell population (OE) compared to the control MSC population (MSC VC). Specifically, the number of cells expressing CD47 was 29.42% in the control MSC population, but increased to 96.02% in the CD47-overexpressing MSC population.

[0077] In addition, the expression levels of mesenchymal stem cell-specific markers in the control mesenchymal stem cell population (MSC VC) and the CD47-overexpressing stem cell population (MSC OE) were compared by flow cytometry using the method described above, and the results are shown in Figure 2.

[0078] As shown in Figure 2, control mesenchymal stem cell population (MSC VC) and CD47 expression Similarly, in the stem cell population (MSC OE), the number of cells expressing mesenchymal stem cell specific markers CD90, CD105, CD73, and CD166 was 98% or more, and the number of cells expressing CD14 and HLA-DR was 1% or less. This indicates that the specific phenotype of mesenchymal stem cells does not change due to the induction of CD47 overexpression.

[0079] <Example 2. Confirmation of the effect in lung tissue by administration of CD47-overexpressing mesenchymal stem cells to an asthma animal model (in vivo)>

[0080] C57BL / 6J female mice (6 weeks old) were obtained from Orient Bio Inc. and acclimatized for 1 week. To induce asthma, 100 μg of Ovalbumin (OVA) (Sigma-Aldrich) and 2 mg of Alum (Sigma-Aldrich) were intraperitoneally administered to the mice on days 0 and 7 (twice in total). Then, mesenchymal stem cells overexpressing CD47 produced in Production Example 2 were intraperitoneally administered on day 20 (5 × 105 cells / 100 μL / mouse). On days 21 to 23, the mice were anesthetized and then 50 μg of OVA (30 uL / mouse) was administered intranasally. On day 24, all mice were sacrificed, and bronchoalveolar lavage fluid (BALF) was obtained with saline (2 ml) using a venous catheter.

[0081] Example 2.1. Confirmation of inflammatory changes in lung tissue

[0082] The obtained lung tissue sections were stained with Hematoxylin and Eosin (H&E) for histological analysis, and the results are shown in FIG.

[0083] As shown in Figure 3, lung tissue inflammation was improved in the control mesenchymal stem cell (MSC VC) administration group, but the degree of improvement in inflammation was significantly greater in the CD47-overexpressing mesenchymal stem cell (MSC OE) administration group compared to the control mesenchymal stem cell administration group.

[0084] <Example 2.2. Confirmation of changes in expression of M1 macrophage-specific markers in lung tissue>

[0085] Lung tissue sections were immunocytochemically stained with integrin αM (CD11b, Abbexa) at a concentration of 1:40, and the degree of CD11b expression was confirmed by attaching Cy3-labeled rabbit anti-mouse IgG1 (Jackson ImmunoResearch Europe Ltd.) as a secondary antibody. The nuclei of cells in the lung tissue were stained with 4',6-diamidino-2-phenylindole (DAPI), and the results are shown in Figures 4 and 5.

[0086] As shown in Figures 4 and 5, when CD47-overexpressing mesenchymal stem cells (MSC OE) were administered to a mouse model of asthma, the expression level of CD11b, an M1 macrophage-specific marker, was reduced compared to the control group administered mesenchymal stem cells (MSC VC).

[0087] <Example 2.3. Confirmation of changes in expression of M2 macrophage cell-specific markers in lung tissue>

[0088] Lung tissue sections were immunocytochemically stained with scavenger receptor cysteine-rich type 1 protein M130 (CD163) (Abbexa) at a concentration of 1:30, and the level of CD163 expression was confirmed by attaching Alexa488-labeled rabbit anti-mouse IgG1 (Jackson ImmunoResearch Europe Ltd.) as a secondary antibody. The nuclei of cells in the lung tissue were stained with DAPI, and the results are shown in FIGS.

[0089] As shown in Figures 6 and 7, when CD47-overexpressing mesenchymal stem cells (MSC OE) were administered to a mouse model of asthma, the expression level of CD164, an M2 macrophage-specific marker, was increased compared to the control group and the mesenchymal stem cell (MSC VC)-administered group.

[0090] <Example 2.4. Confirmation of the number of cells that migrated to lung tissue after intravenous administration>

[0091] Lung tissue sections were immunocytochemically stained with anti-β2 microglobulin antibody (β-2MG, Abcam) at a concentration of 1:300, and the expression level of β-2MG was confirmed by attaching Alexa488-labeled rabbit anti-mouse IgG1 (Jackson ImmunoResearch Europe Ltd.) as a secondary antibody. The nuclei of cells in the lung tissue were stained with DAPI, and the results are shown in Figures 8 and 9.

[0092] As shown in Figures 8 and 9, when CD47-overexpressing mesenchymal stem cells (MSC OE) were administered to a mouse model of asthma, the expression level of β-2MG in lung tissue was higher than that in the control group (MSC VC). This indicates that the number of mesenchymal stem cells that migrated to lung tissue after intravenous administration was higher in CD47-overexpressing mesenchymal stem cells (MSC OE).

[0093] <Example 3. Confirmation of the effect in BALF by administration of CD47-overexpressing mesenchymal stem cells to an asthma animal model (in vivo)>

[0094] <Example 3.1. Confirmation of changes in expression of inflammatory cytokines in BALF>

[0095] The BALF obtained in Example 2 was centrifuged at 1,000 rpm at 4°C for 10 minutes, and mouse tumor necrosis factor-α (mTNF-α) (R&D Systems) was quantified in the separated supernatant by enzyme-linked immunosorbent assay (ELISA). The results are shown in Figure 10.

[0096] As shown in Figure 10, CD47-overexpressing mesenchymal stem cells (MSCs) were administered to a mouse model of asthma. When mice were administered mesenchymal stem cell OE, the amount of mTNF-α secreted as an inflammatory cytokine was the lowest compared to the control group administered mesenchymal stem cells (MSC VC).

[0097] <Example 3.2. Confirmation of the effect of reducing neutrophil cell count in BALF>

[0098] The BALF obtained in Example 2 was centrifuged to sediment the cells, which were then stained with Diff-Quik to measure the number of neutrophil cells. The results are shown in FIG.

[0099] As shown in FIG. 11, the number of neutrophils increased in the asthma-induced mouse model, but decreased in the mesenchymal stem cell administration group, and the largest decrease was observed in the CD47-overexpressing mesenchymal stem cell (MSC OE) administration group.

[0100] <Example 4. Confirmation of immunomodulatory effect of CD47-overexpressing mesenchymal stem cells (in vitro)>

[0101] <Example 4.1. Confirmation of immunomodulatory effect by co-culture with PBMC>

[0102] The mesenchymal stem cells under each condition were co-cultured with human peripheral blood mononuclear cells (PBMCs) (AllCells) activated with 10ng / mL recombinant interleukin 2 (hIL-2) (Miltenyi Biotec) and 5μg / mL phytohemagglutinin-L (PHA-L) (Roche). After 24 hours, the GFP fluorescence expressed in the mesenchymal stem cells was observed and counted under a fluorescent microscope, and the results are shown in Figures 12 and 13.

[0103] As shown in Figures 12 and 13, 70.3% of cells survived in the case of CD47-overexpressing mesenchymal stem cells (MSC OE), while 44.5% of cells survived in the control group mesenchymal stem cells (MSC VC). This indicates that CD47-overexpressing mesenchymal stem cells (MSC OE) are more resistant to activated PBMC apoptosis than the control group mesenchymal stem cells (MSC VC).

[0104] <Example 4.2. Confirmation of immunomodulatory effect by co-culture with NK cells>

[0105] The mesenchymal stem cells under each condition were co-cultured with human natural killer cells (NK cells) (Lonza) activated with 50 IU of IL-2 and 5% human serum (HS) (Sigma-Aldrich) for two weeks. After three hours, the GFP fluorescence expressed in the mesenchymal stem cells was observed and counted under a fluorescent microscope, and the results are shown in Figures 14 and 15.

[0106] As shown in Figures 14 and 15, 63.8% of cells survived in the case of CD47-overexpressing mesenchymal stem cells (MSC OE), while 26.1% of cells survived in the case of control mesenchymal stem cells (MSC VC). This indicates that CD47-overexpressing mesenchymal stem cells (MSC OE) are more resistant to apoptosis caused by activated NK cells than the control mesenchymal stem cells (MSC VC).

[0107] <Example 5. Confirmation of the anti-fibrotic effect of CD47-overexpressing mesenchymal stem cells (in vitro)>

[0108] Human primary lung fibroblasts (HLF) (ATCC) were treated with 5ng / mL of TGF-β1 (R&D Systems), a fibrosis inducer, for 24 hours, and then co-cultured with the same amount of mesenchymal stem cells using a 1μm pore size transwell (BD Falcon). After co-culture was completed, RNA of HLF was obtained using trizol (Invitrogen) and cDNA was synthesized using amfirivert cDNA systhesis platinum master mix (GenDEPOT). To confirm the expression levels of α-smooth muscle actin (α-SMA) and matrix metalloproteinase-13 (MMP-13), which are representative fibrosis markers, from the synthesized cDNA, quantitative real time polymerase chain reaction (qPCR) was performed using LightCycler 480 (Roche), and the results are shown in Figure 16. The sequences of the primers used in PCR are as shown in Table 1 below.

[0109] [Table 1]

[0110] As shown in Figure 16, the expression of representative fibrosis markers, α-SMA and MMP-13, was most significantly decreased in HLF co-cultured with CD47-overexpressing MSC OE compared to the control MSC OE.

Claims

1. A pharmaceutical composition for preventing or treating a lung disease, comprising mesenchymal stem cells expressing CD47 as an active ingredient.

2. The medical composition for preventing or treating a lung disease according to claim 1 , wherein the mesenchymal stem cells are genetically engineered to increase expression of CD47.

3. The pharmaceutical composition for preventing or treating a lung disease according to claim 2 , wherein the genetically engineered mesenchymal stem cells comprise a recombinant vector into which a gene encoding CD47 has been introduced.

4. The pharmaceutical composition for preventing or treating a lung disease according to claim 1, wherein 20% to 99% of the mesenchymal stem cell population expresses CD47.

5. The mesenchymal stem cells are i) positive for at least one marker selected from the group consisting of CD90, CD105, CD73 and CD166; ii) the pharmaceutical composition for preventing or treating a lung disease according to claim 1, which is negative for CD14 or HLA-DR markers.

6. 2. The pharmaceutical composition for preventing or treating a lung disease according to claim 1, wherein the mesenchymal stem cells are derived from any one selected from the group consisting of umbilical cord, umbilical cord blood, placenta, bone marrow, adipose tissue, muscle, amniotic fluid, amniotic membrane and dental pulp.

7. The medical composition for preventing or treating a lung disease according to claim 1 , wherein the mesenchymal stem cells exhibit reduced immunogenicity.

8. The pharmaceutical composition for preventing or treating a lung disease according to claim 1 , wherein the mesenchymal stem cells reduce inflammatory responses in lung tissue.

9. The pharmaceutical composition for preventing or treating a lung disease according to claim 1 , wherein the mesenchymal stem cells expressing CD47 decrease M1 macrophages and increase M2 macrophages.

10. The pharmaceutical composition for preventing or treating a lung disease according to claim 1, wherein the mesenchymal stem cells expressing CD47 reduce the expression of α-SMA (α-smooth muscle actin) and MMP-13 (matrix metalloproteinase-13).

11. The pharmaceutical composition for preventing or treating a pulmonary disease according to claim 1, wherein the pulmonary disease is asthma, pneumonia, chronic obstructive pulmonary disease, bronchitis, emphysema, pulmonary hypertension or pulmonary fibrosis.

12. A method for treating a lung disease, comprising administering to a subject a composition comprising, as an active ingredient, mesenchymal stem cells expressing CD47.

13. Use of mesenchymal stem cells expressing CD47 for the manufacture of a therapeutic agent for the treatment of lung disease.

Citation Information

Patent Citations

  • A platform for generating safe cell therapy drugs

    JP2020530454A

  • Methods for treating allergic airway disease (AAD) / asthma

    JP2020533373A

  • Materials and Methods for Treating Allergic and Inflammatory Conditions

    US20100260725A1

  • Use of umbilical mesenchymal stem cells for treating pulmonary fibrosis

    US20180271917A1